Lemke Laura B, Ge Zhongming, Whary Mark T, Feng Yan, Rogers Arlin B, Muthupalani Sureshkumar, Fox James G
Division of Comparative Medicine, Massachusetts Institute of Technology, 77 Massachusetts Ave., Bldg. 16-825, Cambridge, MA 02139, USA.
Infect Immun. 2009 May;77(5):2147-58. doi: 10.1128/IAI.01395-08. Epub 2009 Feb 17.
Because coinfections can alter helicobacter gastritis, we investigated whether enterohepatic Helicobacter bilis modulates Helicobacter pylori gastritis in C57BL/6 mice. Thirty mice per group were sham dosed, H. bilis or H. pylori infected, or H. bilis infected followed in 2 weeks by H. pylori and then evaluated at 6 and 11 months postinfection (mpi) for gastritis and premalignant lesions. Compared to H. pylori-infected mice, H. bilis/H. pylori-infected mice at 6 and 11 mpi had less severe gastritis, atrophy, mucous metaplasia and hyperplasia (P < 0.01) and, additionally, at 11 mpi, less severe intestinal metaplasia and dysplasia (P < 0.05). H. bilis/H. pylori-infected mice at 11 mpi exhibited less Ki67 labeling of proliferating epithelial cells, reduced numbers of FoxP3(+) T-regulatory (T(REG)) cells, and lower FoxP3(+) mRNA levels than did H. pylori-infected mice (P < 0.05). Proinflammatory interleukin-1beta (IL-1beta), gamma interferon, and tumor necrosis factor alpha mRNA levels were attenuated in H. bilis/H. pylori-infected mice at 6 and 11 mpi (P < 0.01), although anti-inflammatory IL-10, IL-13, and transforming growth factor beta1 mRNA levels were not consistently impacted by H. bilis coinfection. Decreased pathology in H. bilis/H. pylori-infected mice correlated with higher gastric H. pylori colonization at 6 mpi (P < 0.001) and lower Th1-associated immunoglobulin G2c responses to H. pylori at 6 and 10 mpi (P < 0.05). We hypothesized that reduced pathology in H. bilis/H. pylori-infected mice was due to H. bilis-primed T(REG) cells in the lower bowel that migrated to the gastric compartment and inhibited Th1 responses to subsequent H. pylori infection. Thus, H. pylori-induced gastric lesions may vary in mouse models of unknown enteric helicobacter infection status and, importantly, variable sequelae to human H. pylori infection, particularly in developing countries, may occur where coinfection with lower bowel helicobacters and H. pylori may be common.
由于合并感染可改变幽门螺杆菌胃炎,我们研究了肝肠螺杆菌是否会调节C57BL/6小鼠的幽门螺杆菌胃炎。每组30只小鼠分别接受假给药、感染胆汁螺杆菌或幽门螺杆菌,或先感染胆汁螺杆菌,2周后再感染幽门螺杆菌,然后在感染后6个月和11个月评估胃炎和癌前病变情况。与感染幽门螺杆菌的小鼠相比,在感染后6个月和11个月时,同时感染胆汁螺杆菌/幽门螺杆菌的小鼠胃炎、萎缩、黏液化生和增生程度较轻(P<0.01),此外,在感染后11个月时,肠化生和发育异常程度也较轻(P<0.05)。与感染幽门螺杆菌的小鼠相比,感染后11个月的同时感染胆汁螺杆菌/幽门螺杆菌的小鼠增殖上皮细胞的Ki67标记减少、FoxP3(+)调节性T(T(REG))细胞数量减少、FoxP3(+)mRNA水平降低(P<0.05)。在感染后6个月和11个月时,同时感染胆汁螺杆菌/幽门螺杆菌的小鼠促炎白细胞介素-1β(IL-1β)、γ干扰素和肿瘤坏死因子αmRNA水平降低(P<0.01),尽管抗炎性IL-10、IL-13和转化生长因子β1mRNA水平并未因胆汁螺杆菌合并感染而受到持续影响。同时感染胆汁螺杆菌/幽门螺杆菌的小鼠病理变化减轻与感染后6个月时胃幽门螺杆菌定植增加(P<0.001)以及感染后6个月和10个月时对幽门螺杆菌的Th1相关免疫球蛋白G2c反应降低(P<0.05)相关。我们推测,同时感染胆汁螺杆菌/幽门螺杆菌的小鼠病理变化减轻是由于下消化道中由胆汁螺杆菌启动的T(REG)细胞迁移至胃区并抑制了对随后幽门螺杆菌感染产生的Th1反应。因此,在肠道螺杆菌感染状况不明的小鼠模型中,幽门螺杆菌诱发的胃部病变可能有所不同,重要的是,在发展中国家,幽门螺杆菌与下消化道螺杆菌合并感染可能较为常见,这可能导致人类幽门螺杆菌感染出现不同的后遗症。